About Dylan Sammut
Dylan joined Irving Levin in October 2018 as a Research and Editorial Associate and is responsible for reporting on mergers and acquisitions in the healthcare sector. He graduated from Alfred University in May 2014 with a degree in English and Political Science. He currently lives in Bridgeport, CT with his fiancé and his overweight cat, Kimba, and in his free time he plays video games, reads, writes, and hikes on the weekends all year around.
by Dylan Sammut | Jun 16, 2020 9:10 am | Laboratories, MRI & Dialysis
Australian-based Integral Diagnostics (ASX: IDX) announced on June 10 that it acquired Ascot Radiology, expanding its network of diagnostic clinics. The acquisition will create a new entity known as Integral Diagnostics New Zealand Radiology Group, which will have a... Read More »
by Dylan Sammut | Jun 15, 2020 4:50 pm | Behavioral Health Care, Home Health & Hospice
Kindred Healthcare has made a name for itself in the home health sector, but now the healthcare company is looking to expand in the behavioral healthcare space. On June 1, Kindred announced the acquisition of two behavioral health hospitals, WellBridge Greater Dallas... Read More »
by Dylan Sammut | Jun 12, 2020 2:09 pm | Physician Medical Groups
After a brief hiatus from the healthcare M&A market, CRH Medical Corporation (NYSE: CRHM) added two new Georgia-based physician groups to its network in early June. CRH, based in Vancouver, Canada, provides physicians with innovative services and products for the... Read More »
by Dylan Sammut | Jun 12, 2020 1:31 pm | Healthcare Market Updates
The Health Care M&A deals chart is a selection of transactions announced during the prior week(s). The M&A transactions presented here are from our Deal Search Online database, which is updated daily to provide our subscribers with the most up-to-date... Read More »
by Dylan Sammut | Jun 11, 2020 3:21 pm | Biotechnology
AbbVie Inc. (NYSE: ABBV) announced on June 10 a broad oncology collaboration with Denmark-based Genmab A/S (NASDAQ: GMAB). The two firms are teaming up to jointly develop and commercialize three of Genmab’s early-stage investigational bispecific antibody product... Read More »